WEKO3
アイテム
Medical expenses for cilostazol to treat Alzheimer's disease in Japan
https://kokushikan.repo.nii.ac.jp/records/14117
https://kokushikan.repo.nii.ac.jp/records/14117b26eab4a-96ef-4b6f-8b9e-462393affc02
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文 (295.8 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-07-22 | |||||
| タイトル | ||||||
| タイトル | Medical expenses for cilostazol to treat Alzheimer's disease in Japan | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 見出し | ||||||
| 大見出し | 原著 | |||||
| 言語 | ja | |||||
| 見出し | ||||||
| 大見出し | Original | |||||
| 言語 | en | |||||
| 著者 |
KUBOYAMA, Izumi
× KUBOYAMA, Izumi× ITO, Susumu× KAMINAKA, Toshiaki× HATA, Katsuhiko |
|||||
| 著者ID | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | J-GLOBAL ID : 200901011395643320 | |||||
| 著者ID | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | J-GLOBAL ID : 200901012516528555 | |||||
| 著者ID | ||||||
| 内容記述タイプ | Other | |||||
| 著者ID | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | J-GLOBAL ID : 201701008130248251 | |||||
| 著作関係者詳細 | ||||||
| 値 | Toshiaki KAMINAKA Research and Education Center for Natural Sciences Keio University | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Cilostazol (CL) is an antithrombotic agent that was approved for prescribing under Japan’s national health insurance system in 2000. Clinical and experimental studies of CL to treat Alzheimer’s disease (AD) have been reported since 2009. Aims: To use the propensity score method to ascertain whether CL reduced medical expenses among patients with AD in a prefecture of Japan. Methods: Records of 21,181 patients with AD (6,484 males and 14,697 females) from April 2010 to March 2011 were selected from a claims database of the National Health Insurance and the Long-term Care Insurance systems in a prefecture in Japan. Covariates were patient characteristics, comorbidities, and drugs prescribed for AD, i.e. psychoactive agents, narcotics, anticonvulsants, or cholinesterase inhibitors. The outcome variable was medical expenses for the whole year. Results: The propensity score indicated that patients receiving CL had medical expenses ¥10.9 higher than those of patients not receiving CL. Conclusion: According to the propensity score method, CL did not efficiently reduce medical expenses for patients with AD based on claims data. |
|||||
| 書誌情報 |
国士舘大学体育研究所報 en : The annual reports of health physical education and sport science 巻 37, p. 15-21, 発行日 2019-03-31 |
|||||
| 出版者 | ||||||
| 出版者 | 国士舘大学体育学部附属体育研究所 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0389-2247 | |||||
| NCID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00089533 | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 499.09 | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 493.758 | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| キーワード | ||||||
| 主題 | Alzheimer's disease, cilostazol, medical cost, propensity score | |||||
| 注記 | ||||||
| 値 | 表紙の表記 : 第37巻 (平成30年度) | |||||
